Yamauchi K, Tanahashi Y, Okada M, Tsuzuki J, Sato A, Abe K, Inagaki H, Agetsuma H, Hattori R, Izawa H
Department of Medical Information and Medical Records, Nagoya University Hospital, Japan.
Clin Ther. 1995 Jan-Feb;17(1):52-9. doi: 10.1016/0149-2918(95)80006-9.
The long-term effects of niceritrol on lipoprotein(a) (Lp[a]), lipids, apolipoproteins, and fibrinogen and fibrinolytic factors were evaluated in 20 outpatients who had serum Lp(a) levels higher than 20 mg/dL. The mean ( +/- SE) levels of Lp(a) decreased from 33.6 +/- 2.3 mg/dL to 23.5 +/- 3.5 mg/dL after 12 months of niceritrol treatment (P < 0.01). Serum levels of triglycerides and apolipoprotein E decreased significantly and high-density lipoprotein cholesterol (HDL-C) increased significantly after 12 months (P < 0.05). There were no significant changes overall in fibrinogen and fibrinolytic factors, although fibrinogen concentrations showed a tendency to decrease with treatment. PAI-1 levels decreased significantly (P < 0.05) after 6 months of niceritrol treatment. A significant correlation of percent reduction between Lp(a) and apolipoprotein B levels (P < 0.01) was observed, suggesting that the Lp(a)-lowering effects of niceritrol may be due to niceritrol inhibition of apolipoprotein B synthesis, the major apolipoprotein of Lp(a). The ability of niceritrol to decrease Lp(a) levels and increase HDL-C levels, together with its tendency to lower fibrinogen levels, may help prevent coronary events in patients with high levels of Lp(a).
在20名血清脂蛋白(a)[Lp(a)]水平高于20mg/dL的门诊患者中，评估了烟浪丁对Lp(a)、脂质、载脂蛋白、纤维蛋白原和纤维蛋白溶解因子的长期影响。烟浪丁治疗12个月后，Lp(a)的平均（±标准误）水平从33.6±2.3mg/dL降至23.5±3.5mg/dL（P<0.01）。12个月后，甘油三酯和载脂蛋白E的血清水平显著降低，高密度脂蛋白胆固醇（HDL-C）显著升高（P<0.05）。纤维蛋白原和纤维蛋白溶解因子总体上没有显著变化，尽管纤维蛋白原浓度有随治疗而降低的趋势。烟浪丁治疗6个月后，纤溶酶原激活物抑制剂-1（PAI-1）水平显著降低（P<0.05）。观察到Lp(a)降低百分比与载脂蛋白B水平之间存在显著相关性（P<0.01），这表明烟浪丁降低Lp(a)的作用可能是由于其抑制了Lp(a)的主要载脂蛋白——载脂蛋白B的合成。烟浪丁降低Lp(a)水平和升高HDL-C水平的能力，以及其降低纤维蛋白原水平的趋势，可能有助于预防Lp(a)水平高的患者发生冠状动脉事件。
